Quarterly Result12 May 2026, 05:41 pm
Cohance Lifesciences Approves FY26 Audited Results
AI Summary
Cohance Lifesciences Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also approved revisions to the authorized Key Managerial Personnel for determining the materiality of events and disclosures to the stock exchanges. The meeting, held on May 12, 2026, also amended the 'Policy for Determining Material Event or Information' to reflect these changes, effective the same date. The financial results show a revenue from operations of ₹2,030.50 Cr for the year ended March 31, 2026.
Key Highlights
- Audited standalone and consolidated financial results for FY26 approved.
- Revenue from operations for FY26 stands at ₹2,030.50 Cr.
- Revisions to Key Managerial Personnel authorized for materiality determination approved.
- Policy for Determining Material Event or Information amended effective May 12, 2026.